BioCentury on BioBusiness,
Table: EPS watch
Back to the parent article
Monday, November 4, 2013
At least 37 biotechs and pharmas reported earnings
last week. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) fell 11% on
the week, losing $3.9 billion in market value, despite beating the Street's
3Q13 EPS and revenue estimates. Last Wednesday, Jeremy Levin stepped down as
president and CEO (see Cover Story).
Novo Nordisk A/S (CSE:NVO; NYSE:NVO) lost $8.4
billion in market value after posting 3Q13 EPS that missed the Street's
estimate. The pharma also said the preliminary outlook for 2014 indicates high
single-digit growth in sales and operating profit in local currencies. This
compares to its 2013 sales growth guidance of 11-13% and 2013 operating profit
growth guidance of 12-15% in local currencies.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]